You are here: Industry Insights > autoimmune disease

News List

The Coming Successor and the Ending Humira Yi/PharmaSources
March 01, 2023
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
Alpine Immune, Horizon enter autoimmune disease research collaboration Pharmaceutical-Business-Review
December 21, 2021
Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.
Merck signs agreement to buy Pandion Therapeutics for $1.85bn pharmaceutical-technology
March 01, 2021
Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates.
Lenabasum Study for Systemic Sclerosis Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 23, 2020
Corbus Pharmaceuticals has announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a rare and life-threatening multi-system autoimmune disease for which there ...
Eisai Enters Joint Research Alliance to Create SLE Treatment contractpharma
July 14, 2020
Aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus using Eisai’s new oral Toll-Like Receptor 7/8 inhibitor E6742.
Exagen Partners with Sonora Quest to Offer AVISE Testing for Autoimmune Disease americanpharmaceuticalreview
March 17, 2020
Exagen has entered into a strategic partnership with Sonora Quest. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing.
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases b3cnewswire
November 06, 2019
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...
Bio-macromolecular Drugs in the Autoimmune Disease Field in China PharmaSources/1℃
February 13, 2019
Focus on the bio-macromolecular drugs in the autoimmune disease field that have been marketed or in the marketing review stage in China, overall, including 9 marketed drugs and 6 drugs in the marketing review.
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease pharmatimes
November 27, 2018
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
Alvotech teams with Fuji Pharma for biosimilar portfolio in Japan pharmaceutical
November 21, 2018
Alvotech’s products are used in advanced therapies such as oncology, and autoimmune disease. Credit: Alvotech.

Previous page 1 2 Next page